common side effects of vestura
headache
migraine
comprehensive list of adverse effects
needed effects
drospirenone
ethinyl estradiol
unwanted side effects
medical attention
following side effects
taking drospirenone
ethinyl estradiol
check
doctor
drospirenone
ethinyl estradiol
side effects
medical attention
body
medicine
side effects
health care professional
side effects
following side effects
adverse effects
women on oral contraceptive combination products
relative excess
deficiency of the estrogen
progestin components of these formulations
following
frequent adverse effects by relative excess
deficiency of these components
progestin
acne
oily skinbreast tendernessdepressiontiredness
fatiguehair
appetiteweight
gaincholestatic jaundiceprogestin deficiency
late breakthrough bleedingamenorrheahypermenorrheaestrogen
nauseaheadachemelasmahypertensionbreast tendernessedemaestrogen deficiency
early/mid-cycle breakthrough
bleedingincreased spottinghypomenorrhea
general
side effects
exacerbations of systemic lupus erythematosus
porphyria
chorea
possible diminution in lactation
postpartum
flu syndrome
tooth disorder
infection
accidental injury
weight gain
postmarketing experience
number of studies
use of oral contraceptives
risk of ovarian cancer
risk of epithelial ovarian cancers
protection against ovarian cancer
years after discontinuation of oral contraceptives
long term use
years
risk of ovarian cancer
risk of endometrial cancer
protection
years after discontinuation
nulliparous women
higher risk for endometrial carcinoma than other women
incidence of hospitalization for pelvic inflammatory disease
women
taking oral contraceptives
reason for the decrease in the frequency
severity
pelvic inflammatory disease in women
taking oral contraceptives
recent studies
decrease in frequency of functional ovarian cysts
older formulations
women
taking newer low dose formulations
recent study
nurses
health study
long term use of oral contraceptives
long term risk for mortality
cardiovascular
side effects of the estrogen component of this combination drug
hypertension
significant blood pressure increases
women
receiving high-dose estrogen products
mcg
ethinyl estradiol
estrogens
edema
other cardiovascular side effects
aggravation of varicose veins
early investigations of women
taking high dose estrogen combinations
mcg
ethinyl estradiol
such women
increased risk of cardiovascular complications
myocardial infarction
stroke
vascular thrombosis
including
venous thromboembolism
recent large investigations of women
taking low dose estrogen combinations
oral contraceptive use
increased risk of serious cardiovascular complications in healthy non smoking women
age
women
preexisting
preexisting systemic diseases
cardiovascular system
use of oral contraceptives
investigators
new low dose products
adverse effects on lipid metabolism
careful review of a woman
cardiovascular risk factors before a decision
oral contraceptive combinations
frequency of both subarachnoid hemorrhage
thrombotic stroke
investigators
women
taking oral contraceptive hormones
other investigators
risk of these effects for women
using newer low dose formulations
young women
underlying
underlying cardiovascular disease
other risk factors
metabolic side effects
complex alterations in plasma lipid profiles
carbohydrate metabolism
addition
oral contraceptive use
conception delay
progestins
available oral contraceptive combinations
adverse effects on lipid profiles
progestins
antiestrogen
androgen effects
hdl
hdl
cholesterol levels
increase ldl cholesterol levels
estrogens in oral contraceptive combinations
opposing effects
alterations in lipid profiles
relative amount
potency of the specific estrogen
progestin in a
given product
number of investigations
oral contraceptive combinations
glucose tolerance
recent studies with low dose preparations
glucose tolerance
oral contraceptive combinations
adverse effects of oral contraceptives on lipid levels
glucose tolerance
investigators
young diabetic women
existing
existing vascular disease
severe lipidemias
candidates for low dose
oral contraceptive combinations
close monitoring for adverse metabolic effects
gastrointestinal side effects
nausea
treated women
first cycles of therapy
early reports
association between oral contraceptive use
gallbladder disease
abdominal pain
gastroenteritis
postmarketing experience
cases of oral contraceptive-induced esophageal ulceration
geographic tongue
recent studies
risk of gallbladder disease
oncologic side effects
oral contraceptive use
number of studies
possible relationship between the use of oral contraceptives
development of breast cancer
studies
reported conflicting results
committee of the world health organization
studies
risks of breast cancer
numerous studies
overall association between oral contraceptive use
risk of breast cancer
addition
same committee
possible relationship between oral contraceptive use
neoplasms of the uterine cervix
insufficient data
firm conclusions
effects
combined oral contraceptives on the risk of cervical adenocarcinoma
world health organization committee
studies
weak association between long-term use of oral contraceptives
breast cancer
age
age
observed association
bias
development of new cases of cancer
accelerated growth
existing cancers
world health organization committee
increased risk of breast cancer in women over the age
taken oral contraceptives
addition
studies
use of oral contraceptives
specific groups of women
family history of breast cancer
lower risk
variations in the hormonal content of oral contraceptives
risk of breast cancer
studies
potential risk of cervical cancer in patients
taking oral contraceptives
large number of confounding factors
investigations into the epidemiology of this neoplasm
studies
women
taking oral contraceptives
increased risk of dysplasia
epidermoid carcinoma
adenocarcinoma of the cervix
other studies
association
rate of death
hepatocellular carcinoma in the united states
last years
time during which use of oral contraceptive hormones
committee of the world health organization
developing countries
hepatitis b virus infection
hepatocellular carcinoma
short term use of oral contraceptives
increased risk
data on the effects of long term use
recent italian case-control study of women with hepatocellular carcinoma
relative risk of hepatocellular carcinoma
oral contraceptive users
women
oral contraceptives
similar american case-control study
strong association between oral contraceptive use
hepatocellular carcinoma
observed association
actual number of cases of liver cancer in the united states
oral contraceptive use
findings
public health importance in the united states
other western nations
"
hepatic side effects
association with estrogen therapy
therapy with oral contraceptive combinations
focal nodular hyperplasia
intrahepatic cholestasis
liver cell adenomas
hepatic granulomas
hepatic hemangiomas
well-differentiated hepatocellular carcinomas
cases of venous thrombosis
pulmonary embolism
arterial thrombosis
previous thrombotic disease
contraindication
oral contraceptive combinations
hematologic side effects
thromboembolism
use of exogenous estrogens
dose of exogenous estrogens
available preparations
risk
most women
women
age
smoke
women with a previous history of thrombotic diseases
genitourinary side effects
breakthrough bleeding
spotting
first several cycles of oral contraceptive use
non-hormonal causes of such bleeding
vaginitis
dysmenorrhea
candidiasis
metrorrhagia
suspicious papanicolaou smear
vaginal moniliasis
menorrhagia
urinary tract infection
breast pain
dysmenorrhea
menstrual disorder
amenorrhea
urine abnormality
postmarketing experience
women
experienced oligomenorrhea
amenorrhea
following termination of oral contraceptive use
psychiatric side effects
mood changes
depression
precipitation of panic disorder
immunologic side effects
rare reports of oral contraceptive-induced systemic lupus erythematosus
case of fatal pulmonary occlusive disease
oral contraceptive therapy
nervous system
side effects
chorea
association with oral contraceptives
headache
asthenia
postmarketing experience
ocular side effects
retinal thrombosis
addition
manufacturers of oral contraceptive products
patients
developed changes in contact lens tolerance
postmarketing experience
rare reports of eye inflammation
iritis
uveitis
optic neuritis
complete loss of vision
metabolic side effects
use of drospirenone
increased serum potassium levels
musculoskeletal side effects
rare postmarketing reports of osteonecrosis of the jaw
arthralgia
postmarketing experience
hypersensitivity side effects
anaphylactic/anaphylactoid reactions
including urticaria
angioedema
severe reactions with respiratory
circulatory symptoms
respiratory side effects
upper respiratory infection
sinusitis
pharyngitis
sore throat
rhinitis
bronchitis
postmarketing reports
side effects of vestura
fda
healthcare professional for medical advice
breast pain
tenderness
headache
heavy non-menstrual vaginal bleeding
irregular menstrual periods
nausea
normal menstrual bleeding
lasting
heavier menstrual periods
unusual tiredness
weakness
vomiting
stomach pain
chills
clay-colored stools
dark urine
difficulty with breathing
dizziness
fever
headache
itching
loss of appetite
pain in the chest
groin
legs
calves
rash
slurred speech
sudden loss of coordination
severe weakness
numbness in the arm
leg
unexplained shortness of breath
unpleasant breath odor
unusual tiredness
weakness
vision changes
vomiting of blood
yellow eyes
skin
crying
decreased interest in sexual intercourse
delusions of persecution
mistrust
suspiciousness
combativeness
unusual sense of well-being
inability
erection
irritability
loss in sexual ability
desire
drive
performance
mental depression
rapidly changing moods
weight gain